Synopsis Loss of bone mass due to persistently low levels of the hormone estrogen is a significant etiology of osteoporosis. Ninety percent of bone mass is developed in the 18 age of a female. However, due to eating disorders, lack of physical activity, or other health issues females suffers from bone mass deficits leading to osteoporosis in later life. This ‘MEDFACT’ discusses an open-label, randomized, interventional, phase 3 trial to evaluate the effect of treatment of romosozumab versus teriparatide in a patient with osteoporosis from ‘ ‘The Lancet’’ journal.
Authors: Bente L Langdahl, Cesar Libanati, Daria B Crittenden, et al. What was the need for this study? Bisphosphonates are the first-line therapy for patients with osteoporosis. However, patients with a low level of bone mineral density (BMD) or those who have developed fractures during the treatment do not respond…
